Luc Biedermann
Appearances
- DateMay 20, 2024BACKGROUND: Etrasimod is an investigational, oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development to treat immune-mediated inflammatory disorders…
Presenter
University of North Carolina School of Medicine - DateMay 21, 2024BACKGROUND: Risankizumab (RZB), a monoclonal antibody targeting interleukin-23 p19, was evaluated for maintenance therapy in patients with moderately to severely active ulcerative colitis (UC) and clinical response to RZB intravenous (IV) induction treatment in a phase 3 double-blind, placebo (PBO)…
Presenter
Speakers
Charité - Universitätsmedizin BerlinMayo Foundation for Medical Education and Research